C4 Therapeutics Inc
NASDAQ:CCCC
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.655
11
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
C4 Therapeutics Inc
C4 Therapeutics Inc
Other Liabilities
C4 Therapeutics Inc
Other Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
C4 Therapeutics Inc
NASDAQ:CCCC
|
Other Liabilities
$87.6m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Liabilities
$33B
|
CAGR 3-Years
4%
|
CAGR 5-Years
16%
|
CAGR 10-Years
28%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Liabilities
$24.4B
|
CAGR 3-Years
63%
|
CAGR 5-Years
29%
|
CAGR 10-Years
39%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Liabilities
$4.5B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Liabilities
$2.5B
|
CAGR 3-Years
56%
|
CAGR 5-Years
50%
|
CAGR 10-Years
44%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Liabilities
$1.8B
|
CAGR 3-Years
35%
|
CAGR 5-Years
13%
|
CAGR 10-Years
23%
|
|
C4 Therapeutics Inc
Glance View
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. The company is headquartered in Watertown, Massachusetts and currently employs 121 full-time employees. The company went IPO on 2020-10-02. The firm is focused on harnessing the body’s natural regulation of protein levels to develop therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. The firm provides technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to synthesize a new class of small molecule protein degraders that are designed to destroy disease-causing proteins, including targets previously considered to be undruggable. The Company’s lead product candidates, CFT7455, is an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma (MM), peripheral T-cell lymphoma (PTCL), and mantle cell lymphoma (MCL). The firm is also developing CFT8634, an orally bioavailable degrader of a protein target called bromodomain containing 9 (BRD9), for synovial sarcoma and SMARCB1-deleted solid tumors.
See Also
What is C4 Therapeutics Inc's Other Liabilities?
Other Liabilities
87.6m
USD
Based on the financial report for Dec 31, 2023, C4 Therapeutics Inc's Other Liabilities amounts to 87.6m USD.
What is C4 Therapeutics Inc's Other Liabilities growth rate?
Other Liabilities CAGR 5Y
-1%
Over the last year, the Other Liabilities growth was 0%. The average annual Other Liabilities growth rates for C4 Therapeutics Inc have been 10% over the past three years , -1% over the past five years .
You don't have any saved screeners yet
